Shots:
Leonard spoke about how Lilly is advancing in the field of metabolic disease research (esp. diabetes)
He also talked about its lead candidate in type 2 diabetes and also discussed its clinical results in detail
The interview summarizes Lilly’s objective to advance new discoveries and redefine diabetes care
Smriti: Tell us how Lilly is leading…
Shots:
Dr. Mason spoke about the key findings from their in vitro study demonstrating EPA + statins effects in reduced lipid oxidation, which were presented at the ACC 2022
He also spoke about the study design of the REDUCE-IT trial and its importance in the approval of its candidate in metabolic and cardiovascular diseases
The interview summarizes…

